Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting ant...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Proc Natl Acad Sci U S A
Huvudupphovsmän: Mousa, Jarrod J., Sauer, Marion F., Sevy, Alexander M., Finn, Jessica A., Bates, John T., Alvarado, Gabriela, King, Hannah G., Loerinc, Leah B., Fong, Rachel H., Doranz, Benjamin J., Correia, Bruno E., Kalyuzhniy, Oleksandr, Wen, Xiaolin, Jardetzky, Theodore S., Schief, William R., Ohi, Melanie D., Meiler, Jens, Crowe, James E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: National Academy of Sciences 2016
Ämnen:
PNAS Plus
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098655/
https://ncbi.nlm.nih.gov/pubmed/27791117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1609449113
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk